Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812065 | 0.81 | KDM4E (0.59) | TDP1MAP2K1KDM4EPOLBL3MBTL1 | |
| SCHEMBL6032802 | 0.81 | TSHR (0.59) | KDM4EPOLBL3MBTL1ALDH1A1TSHR | |
| SCHEMBL30863406 | 0.80 | KDM4E (0.63) | TDP1KDM4EL3MBTL1ALDH1A1LMNA | |
| SCHEMBL2902900 | 0.80 | KDM4E (0.63) | TDP1KDM4EL3MBTL1ALDH1A1LMNA | |
| SCHEMBL162558 | 0.79 | TDP1 (0.57) | TDP1MAP2K1KDM4EPOLBL3MBTL1 | |
| SCHEMBL69990 | 0.79 | L3MBTL1 (0.62) | TDP1MAP2K1KDM4EPOLBL3MBTL1 | |
| SCHEMBL31185958 | 0.79 | KDM4E (0.57) | TDP1MAP2K1KDM4EPOLBL3MBTL1 | |
| SCHEMBL107721 | 0.79 | KDM4E (0.57) | TDP1MAP2K1KDM4EPOLBL3MBTL1 | |
| SCHEMBL1248162 | 0.79 | P2RX7 (0.66) | TDP1MAP2K1KDM4EPOLBL3MBTL1 | |
| SCHEMBL29416324 | 0.79 | L3MBTL1 (0.62) | TDP1MAP2K1KDM4EPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257390-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | LIEBER INSTITUTE, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257390-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | LIEBER INSTITUTE, INC. | 2023-08-17 | — | — | US | disclosed |
| CN-109456326-A | Organic electroluminescence device, the triarylamine derivative of carbonyl bridging and its application | 苏州大学 | 2019-03-12 | — | — | CN | disclosed |
| US-9617291-B2 | Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617291-B2 | Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-04-11 | — | — | US | disclosed |
| CN-102686587-B | Azaindole glucokinase activators | HOFFMANN LA ROCHE | 2015-05-27 | — | — | CN | disclosed |
| EP-2501703-B1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2501703-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257390-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | POLR2E, POLR2H, POLRMT | TDP1 57/4885MAP2K1 2711/4885KDM4E 3247/4885 |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | TDP1 3307/4885MAP2K1 3370/4885KDM4E 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.